Home › Funds › ACT Capital Partners, L.P. › CBIO
ACT Capital Partners, L.P. position in CBIO
CRESCENT BIOPHARMA INC. · Health Care
ACT Capital Partners, L.P. reported holding 11,500 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q3 2026 13F filing — a position valued at US$168K, representing 0.11% of its reported portfolio and ranking #49 among its reported holdings. ACT Capital Partners, L.P. first reported this position in Q3 2026.
Last updated: 2026-11-07 · Source: SEC EDGAR Form 13F-HR
How ACT Capital Partners, L.P.'s CBIO position evolved
ACT Capital Partners, L.P. first disclosed a stake in CBIO in Q3 2026 at 11,500 shares (US$168K).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 11.50K | $167.78K | New |
About CBIO and 13F data
CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 72 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CBIO
- BVF INC/IL 2.75M sh · $49.48M · Q2 2026
- Fairmount Funds Management LLC 2.75M sh · $49.46M · Q2 2026
- Venrock Adviser, LLC 2.13M sh · $38.40M · Q2 2026
- Logos Global Management LP 1.90M sh · $34.20M · Q2 2026
- FCPM III SERVICES B.V. 1.68M sh · $30.20M · Q2 2026
- Vestal Point Capital, LP 1.63M sh · $29.34M · Q2 2026
- Opaleye Management Inc. 1.32M sh · $23.75M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M sh · $20.88M · Q2 2026
- Boxer Capital Management, LLC 453.69K sh · $8.17M · Q2 2026
- NEXTBio Capital Management LP 372.86K sh · $6.71M · Q2 2026
- Remedium Capital Partners, LLC 361.25K sh · $6.50M · Q2 2026
- STEMPOINT CAPITAL LP 182.38K sh · $3.28M · Q2 2026
More on ACT Capital Partners, L.P.
FAQ
How long has ACT Capital Partners, L.P. held CBIO?
ACT Capital Partners, L.P. has disclosed CBIO holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is ACT Capital Partners, L.P.'s current position in CBIO?
As of Q3 2026, ACT Capital Partners, L.P. holds 11.50K shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $167.78K, representing 0.11% of its reported portfolio and ranking #49.
Has ACT Capital Partners, L.P. been buying or selling CBIO?
In the latest 13F filing (Q3 2026), ACT Capital Partners, L.P. newly opened its position in CBIO.
Which other funds hold CBIO?
Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.